The regulatory pathway for nicotine pouch products in the United States continues to evolve. For manufacturers seeking market authorization through the FDA’s Premarket Tobacco Product Application (PMTA) process, success requires not only robust scientific evidence but also a clear regulatory strategy.
Labstat recently hosted a roundtable webinar bringing together experts in regulatory affairs, in vitro toxicology, chemistry, legal strategy, and product development to discuss the FDA’s Nicotine Pouch Pilot Program and what it means for companies preparing PMTAs.
Moderated by Dr. Pete Gibbons, the roundtable featured insights from panelists Beth Oliva, Stan Gilliland, Peter Joza, and Bonnie Coffa, who discussed the scientific, regulatory, and strategic considerations required to support successful PMTA submissions and bring nicotine pouch products to market. Below are several key insights that emerged from the conversation.
Understanding the FDA Nicotine Pouch Pilot Program
The FDA’s nicotine pouch pilot program represents an effort by the agency to increase engagement with applicants earlier in the PMTA process. While the regulatory standard remains unchanged, the program allows manufacturers to better understand FDA expectations and refine their scientific programs before submission.
Panelists emphasized that the pilot program does not lower the evidentiary bar. Instead, it provides an opportunity for more productive dialogue between regulators and industry, helping companies align their development strategies with FDA expectations under the Appropriate for the Protection of Public Health (APPH) standard.
The APPH Standard Remains Central
As discussed by regulatory attorney Beth Oliva, demonstrating that a product meets the APPH standard remains the central requirement of any PMTA submission. This determination requires evaluating both the potential benefits for adult smokers and the risks of youth initiation.
Importantly, a PMTA should not simply be viewed as a collection of scientific studies. Successful submissions present a cohesive regulatory narrative, integrating evidence from toxicology, chemistry, clinical pharmacology, behavioral science, and population-level risk assessments.
Common Pitfalls in PMTA Submissions
The panel highlighted several recurring challenges that have led to delays or deficiencies in past submissions.
One of the most common issues is document organization. PMTAs are complex submissions that can span thousands of pages. Clear structure, well-organized sections, and properly linked cross-references are critical for helping FDA reviewers efficiently navigate the data.
Another frequent challenge involves ingredient disclosure, particularly when flavour systems are sourced from third-party suppliers. Manufacturers should work closely with flavour houses to ensure that all formulation components and supporting toxicological information can be fully disclosed to the FDA.
Toxicology Considerations for Nicotine Pouches
The discussion also explored how toxicology strategies for nicotine pouch products may differ from those used for other tobacco product categories such as ENDS.
For example, in the on! Plus PMTA Technical Project Lead (TPL) review, product-specific in vitro toxicology studies were not included in the submission. Instead, the application relied on published literature on nicotine pouch toxicology, supported by analytical data showing that the on! Plus products contained low levels of harmful and potentially harmful constituents (HPHCs) and had a product composition sufficiently similar to other nicotine pouches evaluated in the literature, enabling a scientific bridging approach to existing in vitro toxicity data.
This suggests that literature bridging may be acceptable when products are sufficiently similar and when HPHC levels remain comparable to those of other authorized oral nicotine products.
However, panelists noted that product-specific toxicology testing may still be warranted in cases where:
- Novel ingredients or flavour compounds are introduced.
- Ingredient levels exceed established toxicological thresholds.
- The product formulation differs significantly from existing products.
Early toxicological screening using regulatory assays, including in vitro genotoxicity assays and mechanistic platforms such as ToxTracker, was recommended as part of product development. Ingredient-level toxicological assessments are also an important component of nicotine pouch safety evaluations.
Compared with ENDS products, the likelihood of needing a full quantitative risk assessment (QRA) for nicotine pouches is generally lower. Risk assessments for this category more commonly focus on:
- Ingredient-level safety assessments.
- Comparable nicotine exposure.
- Semi-quantitative comparisons of HPHCs to comparator products such as moist snuff, snus, and cigarettes.
A full QRA is typically only necessary when qualitative evaluation suggests a potential increase in toxicity relative to comparator products.
Regulatory and Legal Perspectives
From a regulatory and legal standpoint, Stan Gilliland highlighted two areas receiving particular attention from FDA reviewers: abuse liability and nicotine pharmacokinetics (PK).
The FDA increasingly expects data demonstrating how product characteristics, such as nicotine form and dissolution rate, influence nicotine delivery and the potential for adult smokers to switch from combustible products.
Panelists also cautioned against over-reliance on bridging strategies. While bridging can reduce the amount of testing required across product variants, it must be supported by appropriate analytical data demonstrating scientific comparability.
Chemistry and Product Characterization
Comprehensive product characterization remains a fundamental requirement for PMTA submissions.
Analytical chemistry programs must characterize nicotine content, HPHCs, and product stability across the product’s shelf life. Stability studies are particularly important for nicotine pouch products to ensure that impurities such as myosmine and anatabine remain below acceptable thresholds over time.
Panelists also emphasized the importance of conducting early pilot studies during nicotine pouch product development, prior to initiating formal PMTA testing. These studies help ensure that analytical methods are fit for the specific product matrix and pouch format, particularly when different nicotine forms, flavour systems, or pH conditions may influence nicotine stability or analytical performance. Pilot work can also help demonstrate consistent manufacturing and product characteristics, which is critical before advancing to larger regulatory testing programs.
Marketing and Youth Risk Considerations
Beyond scientific evidence, FDA closely evaluates marketing plans when reviewing PMTAs. Even products supported by robust scientific data may face regulatory challenges if marketing strategies raise concerns regarding youth appeal.
Successful applications must demonstrate appropriate safeguards to prevent youth uptake while still supporting harm reduction potential for adult tobacco users.
The panel also noted the importance of child-resistant packaging for nicotine pouch products. Ensuring that packaging meets established child-resistant standards is a critical component of reducing accidental exposure risks and is an important consideration in FDA’s broader evaluation of product safety and youth protection.
Strategic Product Portfolio Planning
Another important theme was the value of strategic product portfolio selection.
Rather than submitting large numbers of product variants simultaneously, manufacturers may benefit from focusing on a smaller number of well-characterized products supported by strong scientific evidence. This approach allows companies to concentrate resources on building high-quality data packages that clearly demonstrate product safety and regulatory compliance.
Moving Forward
As the nicotine pouch category continues to grow, bringing a product to market will require early planning, robust science, and collaboration across multiple disciplines.
The Labstat roundtable reinforced that successful PMTA submissions depend on integrating analytical chemistry, toxicology, regulatory strategy, and legal considerations into a cohesive development plan. Programs like the FDA nicotine pouch pilot initiative offer valuable opportunities for early engagement, but ultimately, regulatory success will depend on the strength and clarity of the supporting scientific evidence.
About the Webinar
Labstat’s Nicotine Pouch Roundtable brought together experts in regulatory affairs, toxicology, chemistry, and legal strategy to discuss the evolving regulatory landscape for nicotine pouch products and practical considerations for PMTA preparation.
For companies navigating the PMTA pathway, the discussion underscored a critical message:
Successful submissions require more than data. They require a clear and well-structured scientific and regulatory story.
Contact our team to talk about how Labstat can support your nicotine pouch PMTA.
